

DAFTAR PUSTAKA

1. American Cancer Society. Breast cancer facts and figures 2022-2024. American Cancer Society. 2022. p. 1–44.
2. WHO. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2022;149(4):778–89.
3. Scharlier M. The elimination of cancer. *Br J Tuberc*. 2020;1(2):180–1.
4. Ikhuoria EB, Bach C. Introduction to Breast Carcinogenesis – Symptoms, Risks factors, Treatment and Management. *Eur J Eng Res Sci*. 2018;3(7):58.
5. AGUSTINA R. HUBUNGAN DERAJAT DIFERENSIASI HISTOPATOLOGIK DENGAN REKURENSI KANKER PAYUDARA DI RUMAH SAKIT UMUM ABDUL MOELOEK BANDAR LAMPUNG Oleh. 2015;6.
6. EVELINE K, PURWANTO H, LESTARI P. Faktor Klinis dan Histopatologi serta Hubungannya dengan Kekambuhan Pascaoperasi pada Pasien Kanker Payudara di RSUD Dr. Soetomo, Januari–Juni 2015. *Indones J Cancer*. 2017;11(2):55.
7. Sinjal J, Wiyono W, Mpila D. Identifikasi Drug Related Problems (DRPs) Pada Pasien Congestive Heart Failure (CHF) Di Instalasi Rawat inap RSUP Prof. Dr. R. D. Kandou Manado. *J Ilm Farm*. 2019;7(4):119.
8. PCNE. PCNE. The PCNE Classification V9.01. Europe: Pharmaceutical Care Network Europe Foundation; 2020. 2020;1–10.
9. Wulandari Y, Kumala S, Keban SA, Julian ED. The role of pharmacist in handling drug-related problems in breast cancer patients at Dr. Cipto Mangunkusumo Hospital. *Int J Adv Med*. 2020;7(3):364.
10. Cipolle et al. Cipolle R.J., Strand L.M., Morley P.C. *Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services*. 3rd Ed. New York: Mc-Graw Hill Companies; 2012. Univ Basel. 2012;11–8.
11. RI KK. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. 2018;3(2):91–102.

12. Ernst E. Stocley's Drug Interactions. A Source Book of Adverse Interactions, their Mechanisms, Clinical Importance and Management. Focus Altern Complement Ther. 2001;6(1):49–49.
13. Susilowati S, Septasari FS. Analisis Drugs Related Problems pada Pasien Kanker Payudara di Rumah Sakit Umum Daerah KRMT Wongsonegoro Semarang Tahun 2022. J Ilmu Farm dan Farm Klin. 2024;2(1):26.
14. Firdaus NZ, Susilowati S. Evaluasi Penggunaan Kemoterapi pada Pasien Kanker Payudara di Rumah Sakit Islam Sultan Agung Semarang Tahun 2022. J Ilmu Farm dan Farm Klin. 2023;20(2):155.
15. FADILAH IN. Drug related problems. Med Clin (Barc). 2005;124(7):261–2.
16. Widya AA. Identifikasi Drug Related Problems (DRPs) Kategori Ketidaktepatan Dosis, Kontraindikasi dan Interaksi Obat pada Pasien Kanker Payudara di Instalasi Rawat Inap RSUD Dr. Moewardi Tahun 2018. Skripsi Fak Farm Univ Muhammadiyah Surakarta [Internet]. 2019; Available from: <http://eprints.ums.ac.id/id/eprint/75971>
17. Setyowibowo H, Purba FD, Hunfeld JAM, Iskandarsyah A, Sadarjoen SS, Passchier J, et al. Quality of life and health status of Indonesian women with breast cancer symptoms before the definitive diagnosis: A comparison with Indonesian women in general. PLoS One [Internet]. 2018;13(7):1–11. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053201/>
18. Sari YP, Ali H, Asri A. Identifikasi Ekspresi Gen Myc pada Subkultur MCF-7 Breast Cancer Cell Line dengan Sel Punca. J Kesehat Andalas. 2018;7(3):424.
19. Arafah ABR, Notobroto HB. Faktor Yang Berhubungan Dengan Perilaku Ibu Rumah Tangga Melakukan Pemeriksaan Payudara Sendiri (Sadari). Indones J Public Heal. 2018;12(2):143.
20. Khairunnisa HS. Faktor Resiko Kanker Payudara. J Med Utama. 2021;03(01):1533–7.
21. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet].

- 2019;30(8):1194–220. Available from:
<https://doi.org/10.1093/annonc/mdz173>
22. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer Targets Ther.* 2019;11:151–64.
23. Swantara MD, Rita WS, Suartha N, Agustina KK. Anticancer activities of toxic isolate of *Xestospongia testudinaria* sponge. *Vet World.* 2019;12(9):1434–40.
24. Sporikova Z, Koudelakova V, Trojanec R, Hajdich M. Genetic Markers in Triple-Negative Breast Cancer. *Clin Breast Cancer* [Internet]. 2018;18(5):e841–50. Available from:
<http://dx.doi.org/10.1016/j.clbc.2018.07.023>
25. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann Oncol* [Internet]. 2019;30(5):781–7. Available from:
<https://doi.org/10.1093/annonc/mdz051>
26. WHO. Cancer statistics for the year 2020 Europe: An overview. *Int J Cancer.* 2020;149(4):778–89.
27. Harvey NM. Breast Cancer. *Breast Cancer.* 2022.
28. Adolph R, Dipiro JT. Pharmacotherapy. 2020. 1–23 p.
29. Harianto H, Mutiara R, Surachmat H. Risiko Penggunaan Pil Kontrasepsi Kombinasi Terhadap Kejadian Kanker Payudara Pada Reseptor Kb Di Perjan Rs Dr. Cipto Mangunkusumo. *Maj Ilmu Kefarmasian.* 2005;2(2):84–99.
30. Abbas, Aster K. Robbins Basic Pathology. 9th ed. Philadelphia: Elseiver; 2013.
31. Suparna K, Sari LMKKS. Kanker Payudara: Diagnostik, Faktor Risiko, Dan Stadium. *Ganesha Med.* 2022;2(1):42–8.
32. Kathryn JC, Sireesha V G, Stanley L. Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. *Breast Dis.* 2012;32:35–48.
33. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and

- preventions of breast cancer. *Int J Biol Sci.* 2017;13(11):1387–97.
34. Eliyatkin N, Yalcin E, Zengel B, Aktaş S, Vardar E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. *J Breast Heal.* 2015;11(2):59–66.
 35. Rahmawati H HB. Kepaniteraan di Instalasi Radiologi Rumah Sakit. Muhammadiyah Public Heal J. jakarta; 2021. 139 p.
 36. National Comprehensive Cancer Network (NCCN). Breast Invasive Patient. 2024.
 37. American Society of Clinical Oncology (ASCO). Breast Cancer Facts & Figures 2019-2020. *Surg Oncol.* 2019;15–31.
 38. Smith SM, Wachter K, Burris HA, Schilsky RL, George DJ, Peterson DE, et al. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. *J Clin Oncol.* 2021;39(10):1165–84.
 39. Trevor's K&. Chemotherapeutic drugs. *Emergencies in Pediatric Oncology.* 2012. 105–120 p.
 40. Maksymowicz M, Machowicz P, Korzeniowska A, Baran N, Bielak A, Nowak A, et al. Adverse effects in the management of breast cancer – recent studies. *J Educ Heal Sport.* 2023;37(1):11–24.
 41. Hardjono S, Siswandono, Diyah NW. *Buku Obat Anti Kanker.* 2016.
 42. Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. *Life Sci [Internet].* 2021;278(April):119527. Available from: <https://doi.org/10.1016/j.lfs.2021.119527>
 43. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. *J Clin Oncol.* 2020;38(24):2782–97.
 44. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. *Ann Oncol [Internet].* 2016;27(Supplement 5):v119–33. Available from: <http://dx.doi.org/10.1093/annonc/mdw270>
 45. Lambertini M, Partridge AH. Cyclophosphamide-Free Adjuvant

- Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer. *J Natl Cancer Inst.* 2021;113(10):1274–6.
46. Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, et al. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. *Oncologist.* 2019;24(6):e347–57.
47. Drugs.com. Drug Interaction Checker [Internet]. [Internet]. Available from: https://www.drugs.com/interaction/list/?drug_list=1146-0,810-0
48. Drugbank.com. Drug Interaction Checker [Internet]. Available from: Drugbank.com. Drug Interaction Checker
49. Medscape.com. Drug Interaction Checker [Internet]. Available from: <https://www.medscape.com/>
50. American Cancer Association. Cancer facts & figures 2023. Atlanta: American Cancer Society. 2023. p. 1–4.
51. Herawati A, Rijal S, Arsal ASF, Purnamasari R, Abdi DA. Karakteristik Kanker Payudara. *FAKUMI Med J J Mhs Kedokt.* 2021;1(1):44–53.
52. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin.* 2023;73(1):17–48.
53. Weiderpass E, Meo M, Vainio H. Risk factors for breast cancer, including occupational exposures. *Saf Health Work.* 2011;2(1):1–8.
54. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. *JAMA Oncol.* 2019;5(12):1749–68.
55. Coleman RE, Roodman, Smith, Body, Suva, Vessella. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res.* 2006;12(20 PART 2):6243–9.
56. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. *J Hepatol* [Internet]. 2022;77(6):1598–606. Available from:

<https://doi.org/10.1016/j.jhep.2022.08.021>

57. Lin X, DeAngelis LM. Treatment of brain metastases. *J Clin Oncol*. 2015;33(30):3475–84.
58. NCCN. Breast Cancer Breast Cancer. *J R Soc Med*. 2016;70(8):515–7.
59. Lyon AR, López-Fernández T, Lancellotti P, Thuny F, Abdelhamid M, Aboyans V, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J Cardiovasc Imaging*. 2022;23(10):E333–465.
60. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆. *Ann Oncol*. 2021;32(12):1475–95.
61. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res*. 2020;22(1):1–13.
62. Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. *J Natl Cancer Inst*. 2021;113(8):1005–16.
63. Lawrenti H. Terapi Kanker Payudara Stadium Lanjut HER2 (+). *Cermin Dunia Kedokt*. 2023;50(10):565–9.
64. Yanhil SI, Kambey BI, Tambajong HF. Perbandingan antara ondansetron 4 mg iv dan deksametason 5 mg iv dalam mencegah mual-muntah pada pasien laparotomi dengan anestesia umum. *e-CliniC*. 2016;4(2).
65. Tadesse FA, Leminie AA. Effects of Adriamycin-Cytosan chemotherapy on hematological and electrolyte parameters among breast cancer patients. *Front Oncol*. 2023;13(May):1–10.
66. NHS. University Hospitals Sussex: Suspected Pulmonary Embolism Guidelines. Available from: <https://viewer.microguide.global/BSUH/SPECIALTY#content,2cceab3b-3474-417f-8f82-1f7a8619c54b>

67. Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. *Cancers (Basel)*. 2020;12(8):1–17.
68. Edge SB, Compton CC. The american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010;17(6):1471–4.
69. Djuwarno EN, Marhaba Z, Abdullah R, Baharuddin R, Usuli TC, Ismail NH, et al. Gambaran Pengobatan Pasca Kemoterapi Pasien Kanker Payudara Pada Rumah Sakit Di Provinsi Gorontalo. *J Mandala Pharmacon Indones*. 2023;9(2):374–82.
70. Setiawati NC, Yudiyanta, Samekto W. Pengaruh kadar albumin terhadap tingkat keparahan taxanes induced peripheral neuropathy pada kanker payudara. *Clin J*. 2020;101–8.
71. Begg EJ, Chin PKL. A unified pharmacokinetic approach to individualized drug dosing. *Br J Clin Pharmacol*. 2012;73(3):335–9.
72. Irawati I, Sardjan M. Pola Peresepan Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang. *PHARMADEMICA J Kefarmasian dan Gizi*. 2022;1(2):80–5.
73. Listiana I dan S. 700-1384-1-Sm. *Pharmadematica J Kefarmasian Dan Gizi*. 2012;09(02):58–73.
74. Ahmed JH, Makonnen E, Bisaso RK, Mukonzo JK, Fotoohi A, Aseffa A, et al. Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. *Front Pharmacol*. 2020;11(April):1–14.
75. Swerdlow RH, Burns JM KS. NIH Public Access. *Biochim Biophys Acta*. 2014;8(1842):1219–31.
76. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. *J Clin Oncol*. 2020;38(28):3325–48.
77. da Costa R, Passos GF, Quintão NLM, Fernandes ES, Maia JRLCB, Campos MM, et al. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. *Br J Pharmacol*. 2020;177(14):3127–46.

78. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. *Ann Oncol* [Internet]. 2002;13(2):286–92. Available from: <http://dx.doi.org/10.1093/annonc/mdf027>
79. Wulandari I, Aprianthoro NH, Haris M. Penatalaksanaan Radioterapi Kanker Payudara Teknik IMRT. *J Radiogr Indones*. 2021;15–21.
80. Rafli R, Abdullah D, Sinulingga BY. Gambaran Efek Samping dan Terapi Suportif Pasien Kanker Payudara Pasca Kemoterapi CAF di RSUP M.Djamil Padang. *Baiturrahmah Med J*. 2021;1(1):8–13.
81. Iqbal RM, Ningrum FH, Priharsanti CN. Kadar Ureum Dan Kreatinin Serum. *J Kedokt Diponegoro*. 2018;7(2):813–25.
82. Forster M, Deal AM, Page A, Vohra S, Wardell AC, Pak J, et al. Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer. *Oncologist*. 2024;(June):11–7.
83. Zhang L, Yu Q, Wu X cheng, Hsieh M chin, Loch M, Vivien W, et al. *HHS Public Access*. 2019;169(1):175–87.
84. Liutkauskienė S, Grizas S, Jureniene K, Suipyte J, Statnickaite A, Juozaityte E. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. *BMC Cancer*. 2018;18(1):1–9.